Supplemental Table S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• The study investigates zilovertamab vedotin's treatment effects on participants with metastatic solid tumors, focusing on iHC expression.
• Key findings indicate differences in ROR1 and Ki-67 expression in relation to treatment durations.
• Utilizing a phase 2 study design allows for a deeper understanding of treatment impact across diverse participant responses.
• These results may inform future treatment strategies and patient management for metastatic solid tumors.